Organization
Medeos
1 abstract
Abstract
A COST/UTILITY DECISION ANALYSIS OF RITUXIMAB VS ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF THERAPY. ARGENTINEAN COST AND PREFERENCESOrg: Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, Roche S.A.Q. e I, Internal Medicine Residency, Deutsches Hospital, Hospital Fernandez,